Dr. Hu Zhou 周虎
Chief Physician, Associate Professor
Department of Hematology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Thrombocytopenia, myelodysplastic syndromes, myeloproliferative neoplasms, hemolytic anemia, aplastic anemia, hemophilia, DIC, leukemia, myeloma, and lymphoma.
Dr. Zhou holds a clinical MD in Hematology from Peking Union Medical College and Tsinghua University. Serves as Deputy Director of Hematology at Henan Cancer Hospital and leads the Anemia, MDS/MPN, and Hemostasis wards. Research focuses on pathogenesis of platelet disorders, MDS, MPNs, and red cell diseases. Leads two National Natural Science Foundation projects. Published 20 papers, including seven SCI articles, and edited two books.
Professional roles
- Member, Chinese Medical Association
- National Member, Hemostasis and Thrombosis Group, Chinese Medical Association
- National Member, Hematology Branch, Chinese Geriatrics Society
- Standing Committee Member, Hemophilia Professional Committee, China Rare Disease Alliance
Name order: in Chinese the family name comes first (Zhou Hu). Papers usually list the name as Hu Zhou or Zhou H.
Selected publications
69 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Med (Lausanne), 2026 (senior author): Investigating risk factors and developing a predictive model for venous thromboembolism in patients with sepsis. PubMed 42898272
- J Thromb Haemost, 2026 (senior author): TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study. PubMed 41997562
- Blood Sci, 2026 (senior author): Efficacy and safety of eltrombopag in the treatment of cancer therapy-induced thrombocytopenia: a large-scale, multicenter, retrospective study in China. PubMed 42708124
- Cell Biosci, 2026 (senior author): ROCK2 inhibition suppresses cytotoxic T lymphocyte-mediated platelet destruction in primary immune thrombocytopenia. PubMed 42477845
- Front Med (Lausanne), 2026 (senior author): Development and validation of an interpretable machine learning model for venous thromboembolism risk prediction in patients with lung cancer: a real-world study. PubMed 42487960
- Blood Rev, 2026 (senior author): Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies. PubMed 41381305
- J Thromb Thrombolysis, 2026 (senior author): Comparison of outcomes in autoimmune acquired factor XIII deficiency with and without underlying diseases: a systematic review. PubMed 40745406
- Ann Hematol, 2025 (senior author): Sequential combined bypassing therapy in haemophilia patients with high titer inhibitors: surgical experience. PubMed 40009167
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion